DRADS Capital

The Live Green Company, founded in 2018 and based in Santiago, Chile, specializes in developing plant-based food products aimed at providing healthier and more sustainable alternatives to conventional offerings. The company produces items such as live green burger mixes and pancake mixes, focusing on clean labels and minimally processed ingredients. By leveraging technology, The Live Green Company enhances the taste and nutritional value of its products while adhering to sustainable practices. Their proprietary Recommendation Software utilizes principles from Ancestral Indian Science of Plant Nutrition to create 100% natural formulations, significantly reducing research and development costs and time. Additionally, their production process is designed with a commitment to frugal engineering and circular economy principles, which minimize pollution and resource consumption. As the demand for plant-based foods continues to grow, The Live Green Company is positioned to cater to consumers seeking convenient, delicious, and environmentally friendly food options.

Hyperfine Research Inc. specializes in developing portable magnetic resonance imaging (MRI) scanners, aimed at making medical imaging more accessible. Founded in 2014 and based in Guilford, Connecticut, the company focuses on general anatomical brain imaging and addresses various medical conditions, including headaches, strokes, non-specific muscle weakness, encephalopathy, spinal cord compressions, diabetic foot disease, and musculoskeletal trauma. Within a year of its establishment, Hyperfine successfully produced its first images, and it has since improved the quality and functionality of its imaging technology. The company’s mission is to democratize healthcare by ensuring that medical imaging is available to people worldwide.

Developer of a conversational artificial intelligence platform designed for enterprises to market the brand. The company's platform is spearheading a variety of enterprises across the world towards digital transformation through voice assistants, Chatbots, Telephony or IVR (Interactive voice response), and the user-friendly, affordable, and cross-platform solution, it also helps to create a ChatGPT-like experience using the web pages, knowledge base articles and document repositories and can be made accessible across voice, text, Telephony/IVR and social channels and in multiple languages, it helps enterprises of all sizes to have a branded presence on voice, and deploymore

MarvelBiome, Inc. is a biopharmaceutical company based in Woburn, Massachusetts, that specializes in leveraging microbial populations for the development of treatments for various human diseases. Founded in 2019, the company is dedicated to isolating, identifying, and characterizing these microbes to create novel therapeutic applications. By advancing biopharmaceutical technologies, MarvelBiome aims to enable researchers to improve assay methods and further explore the potential of microbial-based therapies in addressing health challenges.

ROKIT Healthcare specializes in bio-printing technology, focusing on autologous organ regeneration through its proprietary bio-fabrication platforms. This innovative approach supports a range of applications in tissue engineering, material science, and regenerative medicine. By providing advanced three-dimensional printing solutions, ROKIT Healthcare aims to enhance medical practices and improve patient outcomes, enabling physicians to utilize bioprinting in clinical settings for better health and quality of life.

Amylyx Pharmaceuticals, Inc. develops novel therapeutic for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. It offers AMX0035, an investigational therapy and a fixed-dose co-formulation of two active compounds, such as sodium phenylbutyrate and Taurursodiol optimized to treat both the energy crisis in the mitochondria and the toxic, unfolded proteins in the endoplasmic reticulum, disrupting the neurological chain of events that leads to patient suffering. The company’s pipeline includes amyotrophic lateral sclerosis, Wolfram syndrome, and Alzheimer’s diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.

AZTherapies, Inc. is a biopharmaceutical company based in Boston, Massachusetts, focused on discovering and developing innovative treatments for neurodegenerative diseases such as Alzheimer’s, stroke, ALS, and Parkinson’s. Founded in 2011, the company is in the advanced clinical stage with a pipeline that includes its lead candidate, ALZT-OP1. This candidate employs a multi-modal approach targeting neuroinflammation, which is recognized as a key factor in neurodegeneration. The ongoing Phase 3 COGNITE trial, which focuses on early Alzheimer's disease, has been fully enrolled and is set to conclude soon. In addition to Alzheimer's, AZTherapies is also working on therapies for cognitive impairment following stroke, ALS, and other related conditions, aiming to enhance cognitive function and quality of life for patients facing limited treatment options.

REACT Neuro develops artificial intelligence based digital healthcare platform for brain health. The company’s platform supports biomarkers and helps to understand patient’s brain health based on clinically validated peer reviewed exams. The company is based in Cambridge, Massachusetts.

Predictus BioSciences, Inc. was incorporated in 2010 and is based in West Roxbury, Massachusetts.